Tag: Farmabios

Axplora announced the completion of its first research and development batches of exatecan, a camptothecin-class topoisomerase I inhibitor, to establish an additional European source for antibody-drug conjugate (ADC) developers [1]. The company said exatecan development and manufacture are based at its Farmabios site in Gropello Cairoli, Italy, and linked to payload-linker development and bioconjugation operations at its Novasep CDMO site in Le Mans, France [1]. Validation batches are targeted before the end of 2026, with initial GMP supply targeted for late 2027 [1].

Earlier today Farmabios, Novasep and PharmaZell officially confirmed today that they are coming together under the new brand Axplora. This announcement comes just 6...